AR115106A1 - CANCER TREATMENT METHOD AND ENHANCING THE EFFECTIVENESS OF T-CELL REDIRECTION THERAPEUTICS - Google Patents

CANCER TREATMENT METHOD AND ENHANCING THE EFFECTIVENESS OF T-CELL REDIRECTION THERAPEUTICS

Info

Publication number
AR115106A1
AR115106A1 ARP190101309A ARP190101309A AR115106A1 AR 115106 A1 AR115106 A1 AR 115106A1 AR P190101309 A ARP190101309 A AR P190101309A AR P190101309 A ARP190101309 A AR P190101309A AR 115106 A1 AR115106 A1 AR 115106A1
Authority
AR
Argentina
Prior art keywords
therapeutics
effectiveness
enhancing
treatment method
cancer treatment
Prior art date
Application number
ARP190101309A
Other languages
Spanish (es)
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of AR115106A1 publication Critical patent/AR115106A1/en

Links

Abstract

Reivindicación 1: Un método para tratar un cáncer en un sujeto, que comprende administrar una cantidad terapéuticamente eficaz de un anticuerpo biespecífico BCMAxCD3 al sujeto para tratar el cáncer, en donde el sujeto es recidivante o refractario al tratamiento con una terapéutica anterior contra el cáncer. Reivindicación 4: El método de una cualquiera de las reivindicaciones 1 - 3, en donde el anticuerpo biespecífico BCMAXCD3 es un isotipo lgG4 y comprende fenilalanina en la posición 405 y arginina en la posición 409 en la HC1 y leucina en la posición 405 y lisina en la posición 409 en la HC2, en donde la numeración de residuos es de acuerdo con el índice de la UE.Claim 1: A method of treating cancer in a subject, comprising administering a therapeutically effective amount of a bispecific BCMAxCD3 antibody to the subject to treat the cancer, wherein the subject is relapsed or refractory to treatment with prior cancer therapeutics. Claim 4: The method of any one of claims 1-3, wherein the bispecific antibody BCMAXCD3 is an IgG4 isotype and comprises phenylalanine at position 405 and arginine at position 409 at HC1 and leucine at position 405 and lysine at position 409 in HC2, where the waste numbering is in accordance with the EU index.

ARP190101309A 2018-05-16 2019-05-16 CANCER TREATMENT METHOD AND ENHANCING THE EFFECTIVENESS OF T-CELL REDIRECTION THERAPEUTICS AR115106A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862672222P 2018-05-16 2018-05-16

Publications (1)

Publication Number Publication Date
AR115106A1 true AR115106A1 (en) 2020-11-25

Family

ID=73543388

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP190101309A AR115106A1 (en) 2018-05-16 2019-05-16 CANCER TREATMENT METHOD AND ENHANCING THE EFFECTIVENESS OF T-CELL REDIRECTION THERAPEUTICS
ARP190101310A AR115107A1 (en) 2018-05-16 2019-05-16 CANCER TREATMENT METHOD AND ENHANCING THE EFFECTIVENESS OF T-CELL REDIRECTION THERAPEUTICS

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP190101310A AR115107A1 (en) 2018-05-16 2019-05-16 CANCER TREATMENT METHOD AND ENHANCING THE EFFECTIVENESS OF T-CELL REDIRECTION THERAPEUTICS

Country Status (1)

Country Link
AR (2) AR115106A1 (en)

Also Published As

Publication number Publication date
AR115107A1 (en) 2020-11-25

Similar Documents

Publication Publication Date Title
CL2020002945A1 (en) Methods for treating cancers and enhancing the efficacy of t-cell redirection therapeutics
AR110203A1 (en) ANTI-TIM-3 ANTIBODIES FOR COMBINATION WITH ANTI-PD-1 ANTIBODIES
AR109605A2 (en) METHOD FOR TREATING PERIPHERAL VASCULAR DISEASES, COMPOSITION AND USE
PH12021500001A1 (en) Antibodies that target hiv gp120 and methods of use
HRP20231156T1 (en) Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
MX2021008888A (en) Humanized anti-tau antibodies.
RU2018123717A (en) COMBINED TREATMENTS, THEIR APPLICATIONS AND METHODS
EA201070740A1 (en) METHOD OF TREATING BONE FRACTURE WITH ANTIBODIES AGAINST SKLEROSTIN
EA201891495A1 (en) BISPECIFIC ANTI-CD20 / ANTI-CD3 ANTIBODIES FOR THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
MX2023008453A (en) Methods of treating substance abuse.
AR077595A1 (en) COMBINATION TREATMENTS
AR101740A1 (en) COMBINATION AND COMPOSITION THERAPY
BR112018002436A2 (en) combination treatment of methods uses of these
EA201890878A1 (en) METHOD OF TREATMENT OF MEDDALLOBLASTOMES USING EZH2 INHIBITOR
EA202192528A1 (en) COMBINATION OF PD-1 INHIBITORS AND LAG-3 INHIBITORS TO IMPROVE EFFICIENCY IN CANCER TREATMENT
AU2017293423A8 (en) Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
CL2019001749A1 (en) Use of anti-sclerostin antibodies in the treatment of imperfect osteogenesis.
AR086984A1 (en) ANTI-CXCR4 ANTIBODY WITH EFFECTIVE FUNCTIONS AND ITS USE IN CANCER TREATMENT
MX2021007330A (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor.
CR20210514A (en) Use of reboxetine to treat narcolepsy
AR124639A1 (en) COMPOSITION FOR THE TREATMENT OF A VASCULAR DISEASE, THE PREVENTION OF A VASCULAR DISEASE, THE TREATMENT OF HYPERTENSION, OR THE PREVENTION OF HYPERTENSION
CO2023017973A2 (en) Transforming Growth Factor βeta Ligand Traps for Disease Treatment
AR115106A1 (en) CANCER TREATMENT METHOD AND ENHANCING THE EFFECTIVENESS OF T-CELL REDIRECTION THERAPEUTICS
PE20221039A1 (en) METHODS FOR USING ANTI-CD79b IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA
MX2021006654A (en) Use of cocculus hirsutus extract for treating dengue.